Zyversa Therapeutics Stock Cash And Equivalents
| ZVSA Stock | 1.14 0.01 0.87% |
ZyVersa Therapeutics fundamentals help investors to digest information that contributes to ZyVersa Therapeutics' financial success or failures. It also enables traders to predict the movement of ZyVersa Stock. The fundamental analysis module provides a way to measure ZyVersa Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ZyVersa Therapeutics stock.
ZyVersa | Cash And Equivalents |
ZyVersa Therapeutics Company Cash And Equivalents Analysis
ZyVersa Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
ZyVersa Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for ZyVersa Therapeutics is extremely important. It helps to project a fair market value of ZyVersa Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since ZyVersa Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ZyVersa Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ZyVersa Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, ZyVersa Therapeutics has 0.0 in Cash And Equivalents. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
ZyVersa Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ZyVersa Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ZyVersa Therapeutics could also be used in its relative valuation, which is a method of valuing ZyVersa Therapeutics by comparing valuation metrics of similar companies.ZyVersa Therapeutics is currently under evaluation in cash and equivalents category among its peers.
ZyVersa Fundamentals
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (433.2 K) | ||||
| Shares Outstanding | 2.34 M | ||||
| Shares Owned By Insiders | 0.61 % | ||||
| Shares Owned By Institutions | 4.47 % | ||||
| Number Of Shares Shorted | 45.48 K | ||||
| Price To Book | 0.38 X | ||||
| EBITDA | (107.74 M) | ||||
| Net Income | (98.3 M) | ||||
| Total Debt | 8.66 K | ||||
| Book Value Per Share | 27.33 X | ||||
| Cash Flow From Operations | (8.72 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | 491.97 X | ||||
| Target Price | 20.0 | ||||
| Beta | 0.64 | ||||
| Market Capitalization | 2.7 M | ||||
| Total Asset | 22.11 M | ||||
| Retained Earnings | (103.22 M) | ||||
| Working Capital | (6.84 M) | ||||
| Net Asset | 22.11 M |
About ZyVersa Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ZyVersa Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ZyVersa Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ZyVersa Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out ZyVersa Therapeutics Piotroski F Score and ZyVersa Therapeutics Altman Z Score analysis. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 491.97 | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.